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Chronic hepatitis C (CHC) infection is a major health
problem worldwide. The global prevalence is esti-
mated to be 3%, ranging from 0.1% to 12% in differ-
ent countries [1,2]. It is estimated that there are 170
million hepatitis C virus (HCV) carriers in the world.
The incidence of new symptomatic infections has been
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The objective of this research was to investigate the clinical performance of COBAS AMPLICOR
hepatitis C virus (HCV) test version 2.0 Assays (CA V2.0). Eight serial samples with standard
HCV ribonucleic acid (RNA) concentration and 10 times serial dilution of the 500 IU/mL samples
were tested in triplicate by CA V2.0 (the limit of detection was 50 IU/mL). HCV RNA was inves-
tigated with CA V2.0 in 220 specimens from 100 chronic hepatitis C (CHC) patients, 60 chronic
hepatitis B patients, and 60 healthy blood donors. The sensitivity was 99% and the specificity was
98.3%. Sera of 84 naïve CHC patients receiving standard interferon plus ribavirin for 24 weeks
were tested by CA V2.0 and CA V1.0 at weeks 2, 4 and 8. The positive detection rates of CA V2.0
were significantly higher than CA V1.0 at week 2 (60.7% vs. 51.2%; p < 0.01) and week 8 (27.4% vs.
21.4%; p < 0.05). At weeks 2, 4 and 8, the positive predictive values were 90.91%, 83.02% and
78.69% with CA V2.0, and 90.24%, 82.14% and 72.73% with CA V1.0. The negative predictive val-
ues were 58.82%, 77.42% and 86.96% with CA V2.0, and 67.44%, 82.14% and 83.33% with CA
V1.0. However, there was no significant difference between CA V2.0 and CA V1.0 for predicting
sustained virologic response.
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estimated to be 1–3 cases per 100,000 persons annually
[1]. Because the majority of cases are asymptomatic,
the actual incidence of new infections is obviously
much higher.
The enzyme immunoassays (EIAs) that detect anti-
bodies to HCV cannot differentiate between active
and resolved infection. Qualitative HCV RNA assays
detect viral genomes and therefore can both confirm
the presence of active infection and demonstrate its
presence 4–6 weeks before antibody seroconversion
takes place [3]. The application of polymerase chain
reaction (PCR) methods for identification of the HCV
RNA thus provides important data relating to diag-
nosis, monitoring, and treatment of HCV infection.
Moreover, recent studies have shown that treatment
strategies were mainly determined or tailored by HCV
RNA measurements before and/or during treatment
[4,5]. Therefore, qualitative HCV RNA assays have
become an essential tool for both the diagnosis and
monitoring of HCV infection.
HCV RNA can usually be detected in the patient’s
serum within 10–14 days after infection [3]. In clinical
practice, qualitative HCV RNA assay offers the desired
sensitivity and specificity for detecting and confirming
the presence of active infection and for documenting
the response after antiviral treatment. The detection of
HCV RNA by reverse transcription–polymerase chain
reaction (RT–PCR) has been widely developed with
standard ready-to-use assays such as the AMPLICOR
HCV test. This test was successfully automated by
using an integrated PCR system based on COBAS
AMPLICOR technology that fully automates all steps
of PCR amplification and detection. Developed and
manufactured by Roche Diagnostics System, the
COBAS AMPLICOR HCV RNA assay version 1.0 (CA
V1.0; Roche Diagnostic Systems, Branchburg, NJ,
USA) is available worldwide. Recently, a new version
(version 2.0) of the COBAS AMPLICOR HCV RNA
assay (CA V2.0; Roche Diagnostic Systems) has been
developed and marketed.
In this study, we aimed to evaluate the clini-
cal performance of these two versions of COBAS
AMPLICOR HCV RNA assays in terms of sensitivity,
specificity, and reproducibility. We also attempted to
compare the performance characteristics for the pre-
diction of sustained virologic response (SVR) between
these two versions among CHC patients receiving
standard interferon (IFN) and ribavirin combination
therapy.
MATERIALS AND METHODS
Validation test and detection limit test
For reliability test, eight validation nucleic acid panels
with standard HCV RNA concentration (NAP-HCV
000; 0 IU/mL, and NAP-HCV 001-007; 50, 500, 5,000,
50,000, 200,000, 500,000, and 2,000,000 IU/mL; Acro-
Metrix, USA) were processed in triplicate with CA V2.0
(24 tests were performed).
To confirm the limit of detection, NAP-HCV 002
(500 IU/mL) was used for serial dilution in ratios of
1:10; 1:100; 1:1,000; and 1:10,000 (from 50 IU/mL to
0.05IU/mL). All diluted specimens were tested in trip-
licate three times (total nine tests in each concentration)
with CA V2.0 assay.
Sensitivity and specificity tests
The presence of HCV RNA was investigated with CA
V2.0 in 220 specimens consecutively collected from 100
CHC patients, 60 chronic hepatitis B (CHB) patients,
and 60 healthy blood donors. Serum samples from
enrolled individuals were collected on SST Vacutainer
(Becton-Dickinson, Meylan, France), centrifuged, ali-
quoted, stored at −30°C within 90 minute of collection,
and tested with the assay within a period of 3 months.
Eligibility criteria for CHC patients were defined as:
anti-HCV (EIA 3.0; Abbott, North Chicago, IL, USA)
positivity; consecutive serum alanine aminotransferase
levels more than 1.5 times above the upper normal
limit for more than 6 months; chronic hepatitis proven
by liver histopathology; negative for HBsAg (enzyme-
linked immunosorbent assay [ELISA]; Abbott); and
patients without concomitant potential causes of
chronic hepatitis other than HCV infection, such 
as alcoholism, drug-induced scenarios, autoimmune
hepatitis, primary biliary cirrhosis, Wilson’s disease,
α-antitrypsin deficiency, etc. Healthy blood donors
were defined as follows: (1) negative for anti-HCV
(EIA 3.0) and HBsAg (ELISA); (2) normal liver func-
tion test; and (3) no history of drug abuse, transfu-
sion, hepatitis, and of percutaneous risks such as
tattooing, dental procedures, or any operation within
1 year. The sensitivity and specificity of CA V2.0
assay was determined directly from the comparison
of the results with the biological standards.
Clinical performance
Sera of 84 naïve CHC patients receiving combination
therapy with high dose conventional IFN (6 MU 
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subcutaneously three times weekly) plus oral ribavirin
(1,000–1,200 mg daily) for 24 weeks were analyzed
for HCV RNA retrospectively. SVR was defined as
clearance of serum HCV RNA at the end of treatment
and throughout the 24-week follow-up period.
Blood samples were collected at weeks 2, 4 and 8
after initiation of combination therapy. Each sample
was processed in parallel for HCV RNA with both
CA V2.0 and CA V1.0.
Undetectable HCV RNA was used as a prediction
of SVR in CHC patients. In our study, the prognostic
values for combination therapy in these 84 patients
were analyzed in parallel with both CA V2.0 assay
and CA V1.0 assay at weeks 2, 4 and 8. Negative
HCV RNA test results were used as a positive predic-
tion of SVR, and positive RNA test results indicated 
a negative prediction of SVR.
Statistical analyses
The discrepancy between these measures for CA
V2.0 and CA V1.0 were analyzed with χ2 tests for
non-independent sample proportions (McNemar’s
test). A p value < 0.05 was considered statistically 
significant.
RESULTS
Validation tests and detection limit tests
A total of 24 tests were performed with CA V2.0 for
the validation test (triplicate for eight panel members
with standard HCV RNA concentration; NAP-HCV
000-007). Only NAP-HCV 000 (0 IU/mL) showed
negative results in the triplicate test and all the 
other panel members showed positive results with
CA V2.0.
For the limit of detection, each serially diluted
sample was tested nine times with CA V2.0. Samples
with HCV RNA concentration of 50 IU/mL were all
positive. However, some negative results were obtained
below 50 IU/mL (the detection rate of serial dilutions:
50 IU/mL, 100%; 5 IU/mL, 33.3%; 0.5 IU/mL, 33.3%;
0.05 IU/mL, 0%; respectively). Our results indicate
the clinical sensitivity of CA V2.0, which is capable 
of detecting > 50 IU/mL HCV RNA concentration in
clinical specimens.
Sensitivity and specificity tests
A total of 220 tests were performed with CA V2.0 for
sensitivity and specificity. Among the sera from 100
CHC patients, HCV RNA was detectable in 99 (99%)
samples with CA V2.0. HCV RNA was detectable in 1
(1.7%) of 60 CHB patients, and in 1 (1.7%) of 60 healthy
blood donor samples. The sensitivity and specificity
of CA V2.0 assay was 99% and 98.3%, respectively.
Clinical performance: comparison 
between CA V2.0 and V1.0
Of the 84 naïve CHC patients receiving combination
therapy with high dose conventional IFN (6 MU sub-
cutaneously three times weekly) plus ribavirin, the SVR
rate for HCV was 60.7%. At weeks 2, 4 and 8, HCV
RNA was detectable with CA V1.0 in 43 (51.2%), 28
(33.3%), and 18 (21.4%) patients, respectively. On the
other hand, HCV RNA was detectable with CA V2.0
in 51 (60.7%), 31 (36.9%), and 23 (27.4%) patients,
respectively (Table 1; p = 0.0047, 0.083, 0.025 at weeks
2, 4 and 8).
Table 1. Comparison of the sensitivity between CA V1.0 and CA V2.0 assays in HCV RNA detection amongst 84 naïve
chronic hepatitis C patients receiving interferon plus ribavirin combination therapy*†
CA V1.0
Week 2 Week 4 Week 8
Positive Negative Positive Negative Positive Negative
CA V2.0
Positive 43 (51.2%) 8 (9.5%) 28 (33.3%) 3 (3.6%) 18 (21.4%) 5 (6.0%)
Negative 0 33 (39.3%) 0 53 (63.1%) 0 61 (72.6%)
p = 0.0047 p = 0.083 p = 0.025
*Comparison between CA V2.0 assay and CA V1.0 assay in sera of 84 naïve chronic hepatitis C patients receiving interferon (6 MU three
times weekly) plus ribavirin for 24 weeks at weeks 2, 4 and 8 after initiation of combination therapy; †discrepancy between these two
assays was analyzed with χ2 for non-independent sample proportions (McNemar’s test). CA = COBAS AMPLICOR; HCV RNA =
hepatitis C virus ribonucleic acid.
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Overall, as shown in Table 2, the positive predic-
tion values (PPV) for CAV2.0 and CAV1.0 were 90.91%
(30/33) and 90.24% (37/41) at week 2, 83.02% (44/53)
and 82.14% (46/56) at week 4, and 78.69% (48/61) and
72.73% (48/66) at week 8. The negative prediction
values (NPV) for CA V2.0 and CA V1.0 were 58.82%
(30/51) and 67.44% (29/43) at week 2, 77.42% (24/31)
and 82.14% (23/28) at week 4, and 86.96% (20/23) and
83.33% (15/18) at week 8. There was no significant
difference between CA V2.0 and V1.0 for the prediction
of SVR in combination therapy.
DISCUSSION
Despite the improvement achieved by third-generation
EIA, seroconversion of anti-HCV would not be de-
tected until 7 to 8 weeks in approximately 30% of
patients after exposure [3]. Supplemental tests such
as commonly used recombinant immunoblot assay
(RIBA) are usually indicated to make a confirmation.
RIBA is standardized and reproducible, but its clini-
cal application is limited due to being time consum-
ing and relatively expensive. Besides, in clinical
practice, there will be some patients with normal
liver function during long-term follow-up who will
still test positive for RIBA. In contrast, HCV RNA can
usually be detected in the patient’s serum within
10–14 days after infection [3]. Therefore, in order to
confirm the presence of active infection, it would be
more efficient to use nucleic acid tests for circulating
HCV RNA.
An ideal qualitative HCV RNA assay should 
be specific, accurate, reproducible, and standardized.
Moreover, it should also be competent as a monitoring
tool in diagnosis and treatment. To meet these practi-
cal requirements, two commercially available assays,
the second generation branched DNA (bDNA) V2.0
assay (Quantiplex HCV RNA; Bayer Diagnostics) and
the COBAS AMPLICOR HCV Monitor test (COBAS
V2.0; Roche Diagnostic Systems) are widely used.
The bDNA assay is convenient and has excellent
reproducibility, but has a low rate of sensitivity. The
COBAS AMPLICOR HCV monitor test, using compet-
itive RT-PCR, has been semi-automated and modified
to amplify all genotypes equally [6,7]. Our results
demonstrated that the CA V2.0 showed good reliability
in the triplicate validation test with standard HCV
RNA panels. We also showed that samples containing
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> 50 IU/mL of HCV RNA were positive (100%), and
became negative below this level (0–33.3%). This ver-
ified the limit of detection of the COBAS AMPLICOR
HCV assay version 2.0 to be 50 IU/mL. The limit of
detection of the COBAS AMPLICOR HCV assay ver-
sion 1.0 is 1,000 copies/mL [8–10]. Since an interna-
tional unit is equivalent to approximately 0.93–3.1
copies as measured in the COBAS AMPLICOR HCV
formats [11], CA V2.0 is approximately 10-fold more
sensitive than CA V1.0 [6].
The competitive RT-PCR assay is highly sensitive
but is associated with the risk of contamination. In
some previous studies [8–10], CA V1.0 assay showed
high sensitivity (94–100%) and specificity (98.0%). In
our study, the results among CHC, CHB, and healthy
blood donors were compared in terms of serology
and clinical diagnosis. CA V2.0 assay showed good
sensitivity (99%), specificity (98.3%), and had good
reliability. It therefore appears to be a suitable system
for the monitoring and diagnosis of HCV infection.
Only one patient (who had a clinical diagnosis of
CHC but a negative result with CA V2.0) probably
had (1) a low level of circulating HCV RNA below the
analytic sensitivity of CA V2.0 and (2) a PCR priming
site mutation.
Pretreatment HCV RNA measurements have been
found to be one of the independent predictors of a
sustained response after combination therapy with
IFN and ribavirin [7,12]. Moreover, recent studies have
shown that treatment strategies were mainly deter-
mined or tailored by HCV RNA measurements before
and/or during treatment [4,5]. The early disappear-
ance of serum HCV RNA during antiviral therapy
has been found to be associated with a favorable long-
term response [13–17]. Our data showed that CA
V2.0 had better performance than CA V1.0 regarding
clinical performance as well as validation panel. It
has been shown that CA V2.0 rather than V1.0 could
predict the outcome of IFN therapy in both serotype
1 and serotype 2 HCV [18]. However, CA V2.0 did not
yield a higher predictive value of SVR to combina-
tion therapy with standard IFN and ribavirin in our
study. This might suggest that COBAS AMPLICOR
HCV RNA assays, both CA V1.0 and CA V2.0 (com-
bination or isolation), are an ideal method for quali-
tative monitoring of treatment. Overall, as shown in
Table 3, CA V2.0 offers several advantages over CA
V1.0 [6,9,11]. Further studies in terms of quantitative
measurements, especially during different stages of
treatment, are needed to elucidate and compare their
impacts on viral kinetics.
In conclusion, CA V2.0 showed good sensitivity
and specificity and had good reliability in triplicate
test. The lower limit of detection for CA V2.0 was
50 IU/mL. CA V2.0 is more sensitive than CA V1.0 in
the detection of HCV RNA after the beginning of IFN
plus ribavirin therapy for CHC patients. Both CA
V2.0 and V1.0 showed that the viral load was an indi-
cator of SVR. However, there is no significant differ-
ence between CA V2.0 and V1.0 for predicting SVR in
combination therapy.
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